AI Article Synopsis

  • Chronic spontaneous urticaria (CSU) is characterized by recurrent hives and swelling that lasts over six weeks without a known cause, primarily affecting adults, especially women, typically in their 30s to 50s.
  • CSU significantly impacts patients' quality of life and places a strain on healthcare systems, making effective management crucial.
  • Recent advancements in biologic therapies offer new treatment options, and this review aims to explore the latest developments and future prospects in this area for managing CSU.

Article Abstract

Chronic spontaneous urticaria (CSU) is a condition defined by the presence of recurrent urticaria, angioedema, or both, which persist for more than six weeks in duration and occurs in the absence of an identifiable trigger. Both children and adults can develop CSU, although it is more common in adults and in women than in men, with a peak occurrence in the third to fifth decades of life. It imposes a significant burden on patients, families and healthcare systems. The goal of therapy in patients with CSU is to achieve a level of symptom control and improvement in quality of life that is acceptable to the patient, while minimizing therapy-related side effects. The recent introduction of biologic drugs has changed the management of the disease. This work aims to provide a narrative review of the current state of biological therapy and the promising drugs under development for CSU.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431883PMC
http://dx.doi.org/10.23750/abm.v92iS7.12415DOI Listing

Publication Analysis

Top Keywords

biologic drugs
8
chronic spontaneous
8
spontaneous urticaria
8
drugs chronic
4
urticaria chronic
4
csu
4
urticaria csu
4
csu condition
4
condition defined
4
defined presence
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!